Genetic basis of altered central tolerance and autoimmune diseases: A lesson from AIRE mutations

International Reviews of Immunology

Volumn 31, Issue 5, 2012, Pages 344-362

  Capalbo, Donatella ^a   Giardino, Giuliana ^a   Martino, Lucia De ^a   Palamaro, Loredana ^a   Romano, Rosa ^a   Gallo, Vera ^a   Cirillo, Emilia ^a   Salerno, Mariacarolina ^a   Pignata, Claudio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

AIRE; Autoimmune diseases; Autoimmunity; Central tolerance; Susceptibility genes

Indexed keywords

AUTOIMMUNE REGULATOR PROTEIN; IMMUNOSUPPRESSIVE AGENT; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOIMMUNE THYROIDITIS; CELL DIFFERENTIATION; CELL MATURATION; DENDRITIC CELL; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; THYMOCYTE; THYMUS;

AUTOANTIGENS; AUTOIMMUNITY; CENTRAL TOLERANCE; DENDRITIC CELLS; EPITHELIAL CELLS; HUMANS; MUTATION; PERIPHERAL TOLERANCE; POLYENDOCRINOPATHIES, AUTOIMMUNE; T-LYMPHOCYTES; THYMUS GLAND; TRANSCRIPTION FACTORS;

EID: 84867776967     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.697230     Document Type: Article

References (189)

1. Grammatikos A, Tsokos G. Immunodeficiency and autoimmunity: Lessons from systemic lupus erythematosus. TrendsMolMed. 2012;18:101-108.
2. Pessach IM, Notarangelo L. X-linked primary immunodeficiencies as a bridge to better understanding X-chromosome related autoimmunity. J Autoimmun. 2009;33:17-24.
3. Madkaikar M, Mhattre S, Gupta M, Ghosh K. Advances in autoimmune lymphoproliferative syndromes. Eur J Haematol. 2011;87:1-9.
4. De Berardinis P, Ombra MN, Buono C, Toraldo R, Vetrano F, Guardiola J. Long-termculture and T cell receptor analysis of T cell clones isolated froma patient with adenosine deaminase deficiency and type I diabetes. Clin Immunol Immunopathol. 1994;73:362-366.
5. Sneller MC, Strans SE, Jaffe ES, et al. A novel lymphoproliferative/ autoimmune syndrome resemblingmurine Ipr/gld disease. J Clin Invest. 1992;90:334-341.
6. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935-946.
7. Puck JM, Rieux-Laucat F, Le Deist F. Autoimmune lymphoproliferative syndrome. In: Ochs H, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York: Oxford University Press; 2006: 326-341.
8. Niemela JE, Lu L, Fleisher TA, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood. 2011;117:2883-2886.
9. DeFranco S, Bonissoni S, Cerutti F, et al. Defective function of Fas in patients with type 1 diabetes associated with other autoimmune diseases. Diabetes. 2001;50:483-488.
10. Turbyville JC, Koneti Rao V. The autoimmune lymphoproliferative syndrome: A rare disorder providing clues about normal tolerance. Autoimmun Rev. 2010;9:488-493.
11. Holzelova E, Vonarbourg C, Stolzenberg MC, et al. Autoimmune lymphoproliferative syndrome with somatic Fasmutations. N Engl JMed. 2004;351:1409-1418.
12. Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol. 1991;138:1379-1387.
13. Bennett CL,OchsHD. IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr Opin Pediatr. 2001;13:533-538.
14. Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet. 2002;39:537-545.
15. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused bymutations of FOXP3. Nat Genet. 2001;27:20-21.
16. Gambineri E, Perroni L, Passerini L, et al. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: Inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol. 2008;122:1105-1112.
17. Hori S,Nomura T, Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
18. Bacchetta R,Gambineri E, RoncaroloMG. Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol. 2007;120:227-235.
19. Romagnani S. Immunological tolerance and autoimmunity. Intern Emerg Med. 2006;1:187-196.
20. Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol. 2004;126:81-84.
21. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173:1444-1453.
22. Berger CL, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: Malignant proliferation of Tregulatory cells. Blood. 2005;105:1640-1647.
23. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005;65:2457-2464.
24. Chatila TA. Role of regulatory T cells in human diseases. J AllergyClin Immunol. 2005;116:949-959.
25. Roifman CM. Human IL-2 receptor alpha chain deficiency. Pediatr Res. 2000;48:6-11.
26. Miller JF. Immunological function of the thymus. Lancet. 1961;2:748-749.
27. Bleul CC,BoehmT.Chemokines define distinct microenvironments in the developing thymus. Eur J Immunol. 2000;30:3371-3379.
28. Liu C, Ueno T, Kuse S, et al. The role of CCL21 in recruitment of T-precursor cells to fetal thymi. Blood. 2005;105:31-39.
29. Holl̈ander GA,Wang B, Nichogiannopoulou A, et al. Developmental control point in induction of thymic cortex regulated by a subpopulation of prothymocytes. Nature. 1995;373:350-353.
30. van Ewijk W, Hollander G, Terhorst C, Wang B. Stepwise development of thymic microenvironments in vivo is regulated by thymocyte subsets. Development. 2000;127:1583-1591.
31. Klug DB, Carter C, Gimenez-Conti IB, Richie ER. Cutting edge: Thymocyte-independent and thymocyte-dependent phases of epithelial patterning in the fetal thymus. J Immunol. 2002;169:2842-2845.
32. Shortman K,Wu L. Early T lymphocyte progenitors. Annu Rev Immunol. 1996;14:29-47.
33. Wu CY,Warrier RR, Carvajal DM, et al. Biological function and distribution of human interleukin-12 receptor b chain. Eur J Immunol. 1996;246:345-350.
34. Moore TA, Zlotnik A. T-cell lineage commitment and cytokine responses of thymic progenitors. Blood. 1995;86:1850-1860.
35. Lee CK, Kim JK, Kim Y, et al. Generation of macrophages from early T progenitors in vitro. J Immunol. 2001;166:5964-5969.
36. Schmitt TM, Ciofani M, Petrie HT, Z'uniga-Pfl̈ucker JC. Maintenance of T cell specification and differentiation requires recurrent notch receptor-ligand interactions. J Exp Med. 2004;200:469-479.
37. Talebian L, Li Z, Guo Y, et al. T-lymphoid,megakaryocyte, and granulocyte development are sensitive to decreases in CBFbeta dosage. Blood. 2007;109:11-21.
38. Bender TP, Kremer CS, KrausM, Buch T, Rajewsky K. Critical functions for c-Myb at three checkpoints during thymocyte development. Nat Immunol. 2004;5:721-729.
39. Anderson G, JenkinsonWE, Jones T, et al. Establishment and functioning of intrathymicmicroenvironments. Immunol Rev. 2006;209:10-27.
40. von Boehmer H, FehlingHJ. Structure and function of the pre-T cell receptor. Annu Rev Immunol. 1997;15:433-452.
41. Z'uniga-Pfl̈ucker JC, Lenardo MJ. Regulation of thymocyte development from immature progenitors. Curr Opin Immunol. 1996;8:215-224.
42. Fehling HJ, von Boehmer H. Early alpha beta T cell development in the thymus of normal and genetically alteredmice. Curr Opin Immunol. 1997;9:263-275.
43. Kisielow P, Teh HS, Bl ̈uthmann H, von Boehmer H. Positive selection of antigen-specific T cells in thymus by restrictingMHC molecules. Nature. 1988;335:730-733.
44. Jameson SC, Hogquist KA, Bevan MJ. Positive selection of thymocytes. Annu Rev Immunol. 1995;13:93-126.
45. Reichert RA, Weissman IL, Butcher EC. Phenotypic analysis of thymocytes that express homing receptors for peripheral lymph nodes. J Immunol. 1986;136:3521-3528.
46. Bendelac A,Matzinger P, Seder RA, PaulWE, Schwartz RH. Activation events during thymic selection. J ExpMed. 1992;175:731-742.
47. Ramsdell F, Jenkins M, Dinh Q, Fowlkes BJ.The majority of CD4+8 thymocytes are functionally immature. J Immunol. 1991;147:1779-1785.
48. Griesemer AD, Sorenson EC, Hardy MA. The role of the thymus in tolerance. Transplantation. 2010;90:465-474.
49. Cheroutre H. Starting at the beginning: New perspectives on the biology of mucosal T cells. Annu Rev Immunol. 2004;22:217-246.
50. Franki AS, Van Beneden K, Dewint P, et al. Lymphotoxin alpha 1 beta 2: A critical mediator in V alpha 14i NKT cell differentiation.Mol Immunol. 2005;42:413-417.
51. Baldwin TA, Hogquist KA, Jameson SC.The fourth way? Harnessing aggressive tendencies in the thymus. J Immunol. 2004;173:6515-6520.
52. Brewer JA,KanagawaO, Sleckman BP,Muglia LJ.Thymocyte apoptosis induced by T cell activation is mediated by glucocorticoids in vivo. J Immunol. 2002;169:1837-1843.
53. Martin S, Bevan MJ. Antigen-specific and nonspecific deletion of immature cortical thymocytes caused by antigen injection. Eur J Immunol. 1997;27:2726-2736.
54. Palmer E. Negative selection - clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol. 2003;3:383-391.
55. Hammerling GJ. Non-deletional mechanisms of peripheral and central tolerance: Studies with transgenic mice with tissue-specific expression of a foreign MHC class I antigen. Immunol Rev. 1991;122:47-67.
56. McGargill MA, Derbinski JM, Hogquist KA. Receptor editing in developing T cells. Nat Immunol. 2000;1:336-341.
57. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345-352.
58. Pignata C, Troncone R, Monaco G, et al. Impaired suppressor activity in children affected by coeliac disease. Gut. 1985;26:285-290.
59. Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol. 2001;2:1032-1039.
60. Derbinski J, Gabler J, Brors B, et al. Promiscuous gene expression in thymic epithelial cells is regulated atmultiple levels. J ExpMed. 2005;202:33-45.
61. Gray DH, Seach N, Ueno T, et al. Developmental kinetics, turnover, and stimulatory capacity of thymic epithelial cells. Blood. 2006;108:3777-3785.
62. Gray D, Abramson J, Benoist C,Mathis D. Proliferative arrest and rapid turnover of thymic epithelial cells expressing Aire. J ExpMed. 2007;204:2521-2528.
63. Anderson MS, Veneziani ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298:1395-1401.
64. Coutinho A, Caramalho I, Seixas E, Demengeot J. Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection. Curr TopMicrobiol Immunol. 2005;293:43-71.
65. Derbinski J, Pinto S, R̈osch S, Hexel K, Kyewski B. Promiscuous gene expression patterns in single medullary thymic epithelial cells argue for a stochastic mechanism. Proc Natl Acad Sci U S A. 2008;105:657-662.
66. Gabler J, Arnold J, Kyewski B. Promiscuous gene expression and the developmental dynamics of medullary thymic epithelial cells. Eur J Immunol. 2007;37:3363-3372.
67. Gillard GO, Farr AG. Features of medullary thymic epithelium implicate postnatal development in maintaining epithelial heterogeneity and tissue-restricted antigen expression. J Immunol. 2006;176:5815-5824.
68. Kyewski B, Peterson P. Aire,master ofmany trades. Cell. 2010;140:24-26.
69. Mathis D, Benoist C. A decade of AIRE. Nat Rev Immunol. 2007;7:645-650.
70. Mathis D, Benoist C. Aire. Annu Rev Immunol. 2009;27:287-312.
71. Villasenor J, Besse W, Benoist C, Mathis D. Ectopic expression of peripheral-tissue antigens in the thymic epithelium: Probabilistic, monoallelic, misinitiated. Proc Natl Acad Sci U S A. 2008;105:15854-15859.
72. Rooke R,Waltzinger C, Benoist C,MathisD. Targeted complementation ofMHCclass II deficiency by intrathymic delivery of recombinant adenoviruses. Immunity. 1997;7:123-134.
73. Scollay R, Godfrey DI. Thymic emigration: Conveyor belts or lucky dips? Immunol Today. 1995;16:268-274.
74. Klein L. Deadman walking: How thymocytes scan the medulla. Nat Immunol. 2009;10:809-811.
75. Koble C, Kyewski B.Thethymic medulla: A unique microenvironment for intercellular self-antigen transfer. J ExpMed. 2009;206:1505-1513.
76. Millet V,Naquet P,Guinamard RR. IntercellularMHCtransfer between thymic epithelial and dendritic cells. Eur J Immunol. 2008;38:1257-1263.
77. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: Regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005;6:331-337.
78. LiuH, LeungBP.CD4+CD25+ regulatory T cells in health and disease.Clin Exp Pharmacol Physiol. 2006;33:519-524.
79. Cabarrocas J,CassanC,Magnusson F, et al. Foxp3+ CD25+ regulatoryT cells specific for aneo-selfantigen develop at the double-positive thymic stage. Proc Natl Acad Sci U S A. 2006;30:8453-8458.
80. Jordan MS, BoesteanuA,Reed AJ, et al.Thymic selection ofCD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol. 2001;2:301-306.
81. Caton AJ, Cozzo C, Larkin J, LermanMA, Boesteanu A, JordanMS. CD4(+) CD25(+) regulatory T cell selection. Ann N Y Acad Sci. 2004;1029:101-114.
82. D'Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol. 2005;6:1152-1159.
83. Kim JM, Rudensky A.Therole of the transcription factor Foxp3 in the development of regulatory T cells. Immunol Rev. 2006;212:86-98.
84. Van Santen HM, Benoist C, Mathis D. Number of T reg cells that differentiate does not increase upon encounter of agonist ligand on thymic epithelial cells. J ExpMed. 2004;200:1221-1230.
85. Foy TM, Page DM,Waldschmidt TJ, et al. An essential role for gp39, the ligand for CD40, in thymic selection. J ExpMed. 1995;182:1377-1388.
86. Page DM, Roberts EM, Peschon JJ,Hedrick SM. TNF receptor-deficient mice reveal striking differences between severalmodels of thymocyte negative selection. J Immunol. 1998;160:120-133.
87. Matzinger P,Guerder S.Does T-cell tolerance require a dedicated antigen-presenting cell?Nature. 1989;338:74-76.
88. Kishimoto H, Sprent J. Several different cell surface molecules control negative selection of medullary thymocytes. J ExpMed. 1999;190:65-73.
89. Kishimoto H, Sprent J. Negative selection in the thymus includes semimature T cells. J Exp Med. 1997;185:263-271.
90. Kishimoto H, Surth CD, Sprent J. A role for Fas in negative selection of thymocytes in vivo. J Exp Med. 1998;187:1427-1438.
91. Cloosen S, Arnold J,Thio M, Bos GM, Kyewski B, GermeraadWT. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: Implications for self-tolerance and tumor therapy. Cancer Res. 2007;67:3919-3926.
92. Chentoufi AA, Palumbo M, Polychronakos C. Proinsulin expression by Hassall's corpuscles in the mouse thymus. Diabetes. 2004;53:354-359.
93. Chentoufi AA, Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: The mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes. 2002;51:1383-1390.
94. Brimnes MK, Jensen T, Jørgensen TN, Michelsen BK, Troelsen J, Werdelin O. Low expression of insulin in the thymus of non-obese diabetic mice. J Autoimmun. 2002;19:203-213.
95. Giraud M, Taubert R, Vandiedonck C, et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature. 2007;448:934-937.
96. Anderson AC, Nicholson LB, Legge KL, Turchin V, Zaghouani H, Kuchroo VK. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: Mechanisms of selection of the self-reactive repertoire. J ExpMed. 2000;191:761-770.
97. Klein L, KlugmannM,Nave KA, Tuohy VK, Kyewski B. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat Med. 2000;6:56-61.
98. Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature. 2003;426:454-460.
99. Calanan B, Szychowski S, Chan FK, Cado D, Winoto A. A role for the orphan steroid receptorNur77 in apoptosis accompanying antigen-induced negative selection. Immunity. 1995;3:273-282.
100. Cavadini P, Vermi W, Facchetti F, et al. AIRE deficiency in thymus of 2 patients with Omenn syndrome. J Clin Invest. 2005;115:728-732.
101. Honig M, Schwarz K. Omenn syndrome: A lack of tolerance on the background of deficient lymphocyte development andmaturation. Curr Opin Rheumatol. 2006;18:383-388.
102. Davies JK, Telfer P, Cavenagh JD, Foot N,Neat M. Autoimmune cytopenias in the 22q11.2 deletion syndrome. Clin Lab Haematol. 2003;25:195-197.
103. Sakamoto O, Imaizumi M, Suzuki A, et al. Refractory autoimmune hemolytic anemia in a patient with chromosome 22q11.2 deletion syndrome. Pediatr Int. 2004;46:612-614.
104. Sullivan KE, McDonald-McGinn DM, Driscoll DA, et al. Juvenile rheumatoid arthritis-like polyarthritis in chromosome 22q11.2 deletion syndrome (DiGeorge anomalad/velocardiofacial syndrome/ conotruncal anomaly face syndrome). Arthritis Rheum. 1997;40:430-436.
105. Brown JJ, Datta V, Browning MJ, Swift PG. Graves' disease in DiGeorge syndrome: Patient report with a review of endocrine autoimmunity associated with 22q11.2 deletion. J Pediatr Endocrinol Metab. 2004;17:1575-1579.
106. Jawad AF, McDonald-McGinn DM, Zackai E, Sullivan KE. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr. 2001;139:715-723.
107. Gennery AR. Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome. Arch Dis Child. 2002;86:422-425.
108. McLean-Tooke A, Spickett GP, Gennery AR. Immunodeficiency and autoimmunity in 22q11.2 deletion syndrome. Scand J Immunol. 2007;66:1-7.
109. Kramradt T, Goggel R, Erb KJ. Induction, exacerbation and inhibition of allergic and autoimmune diseases by infection. Trends Immunol. 2005;26:260-267.
110. McLean-Tooke A, Barge D, Spickett GP, Gennery AR. Immunologic defects in 22q11.2 deletion syndrome. J Allergy Clin Immunol. 2008;122:362-367.
111. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet. 1997;17:393-398.
112. Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet. 1997;17:399-403.
113. Aaltonen J, Horelli-Kuitunen N, Fan JB, et al. High-resolution physical and transcriptional mapping of the autoimmune polyendocrinopathy-candidiasis- ectodermal dystrophy locus on chromosome 21q22.3 by FISH. Genome Res. 1997;7:820-829.
114. Ferguson BJ, Alexander C, Rossi SW, et al. AIRE's CARD revealed, a new structure for central tolerance provokes transcriptional plasticity. J Biol Chem. 2008;283:1723-1731.
115. Pitkenen J, Rebane A, Rowell J, et al. Cooperative activation of transcription by autoimmune regulator AIRE and CBP. Biochem Biophys Res Commun. 2005;333:944-953.
116. Ramsey C, Burkrinsky A, Peltonen L. Systematic mutagenesis of the functional domains of AIRE reveals their role in intracellular targeting. HumMol Genet. 2002;11:3299-3308.
117. Gibson TJ, Ramu C, Gemund C, Aasland R. The APECED polyglandular autoimmune syndrome protein, AIRE-1, contains the SAND domain and is probably a transcription factor. Trends Biochem Sci. 1998;23:242-244.
118. Ilmarinen T, Eskelin P,HalonenM, et al. Functional analysis of SANDmutations in AIRE supports dominant inheritance of the G228Wmutation. HumMutat. 2005;26:322-331.
119. Bottomlei MJ, Stier G, Pennacchini D, et al. NMR structure of the first PHD finger of autoimmune regulator protein (AIRE1): Insights into autoimmune polyendocrinopathy-candidiasisectodermal dystrophy (APECED) disease. J Biol Chem. 2005;280:11505-11512.
120. Bjorses P, Halonen M, Palvimo JJ, et al.Mutation in the AIRE gene: Effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein. AmJ HumGenet. 2000;66:378-392.
121. Meloni A, Incani F, Corda D, Cao A, Rosatelli MC. Role of PHD fingers and COOH-terminal 30 amino acids in AIRE transactivation activity.Mol Immunol. 2008;45:805-809.
122. HalonenM, Kangas H, Ruppell T, et al. APECED-causingmutations in AIRE reveal the functional domains of the protein. HumMutat. 2004;23:245-257.
123. Uchida D,Hatakeyama S,Matsushima A, et al. AIRE functions as an E3 ubiquitin ligase. J ExpMed. 2004;199:167-172.
124. Savkur RS, Burris TP. The coactivator LXXLL nuclear receptor recognition motif. J Pept Res. 2004;63:207-212.
125. Johnnidis JB, Venanzi ES, Taxman DJ, Ting JP, Benoist CO,Mathis DJ. Chromosomal clustering of genes controlled by the aire transcription factor. Proc Natl Acad Sci USA. 2005;17:7233-7238.
126. Abramson J, Giraud M, Benoist C,Mathis D. Aire's partners in the molecular control of immunological tolerance. Cell. 2010;140:123-135.
127. Pitkanen J, Vahamurto P, Krohn K, Peterson P. Subcellular localization of the autoimmune regulator protein: Characterization of nuclear targeting and transcriptional activation domain. J Biol Chem. 2001;276:19597-19602.
128. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem Pharmacol. 2004;68:1145-1155.
129. Peterson P, Org T,RebaneA. Transcriptional regulation by AIRE:molecularmechanisms of central tolerance. Nat Rev Immunol. 2008;8:948-957.
130. Liiv I, Rebane A, Org T, et al. DNA-PK contributes to the phosphorylation of AIRE: Importance in transcriptional activity. Biochim Biophys Acta. 2008;1783:74-83.
131. Ilmarinen T, Kangas H, Kytomaa T, et al. Functional interaction of AIRE with PIAS1 in transcriptional regulation.Mol Immunol. 2008;45:1847-1862.
132. Oven I, Brdickova N, Khoutek J, Vaupotic T, Narat M, Peterlin BM. AIRE recruits P-TEFb for transcriptional elongation of target genes in medullary thymic epithelial cells. Mol Cell Biol. 2007;27:8815-8823.
133. Mellor J. It takes a PHD to read the histone code. Cell. 2006;126:22-24.
134. OrgT,Chignola F,HetenyiC, et al.Theautoimmune regulatorPHDfinger binds to non-methylated histone H3K4 to activate gene expression. EMBO Rep. 2008;9:370-376.
135. Koh AS, Kuo AJ, Park SY, et al. Aire employs a histone-bindingmodule to mediate immunological tolerance, linking chromatin regulation with organ-specific autoimmunity. Proc Natal Acad Sci USA. 2008;105:15878-15883.
136. Cohen JN,Guidi CJ, Tewalt EF, et al. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J ExpMed. 2010;207:681-688.
137. SeachN, Ueno T, Fletcher AL, et al.The lymphotoxin pathway regulates Aire-independent expression of ectopic genes and chemokines in thymic stromal cells. J Immunol. 2008;180:5384-5392.
138. Kim SH, Jeong JW, Park JA, et al. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep. 2007;17:647-651.
139. Eldershaw SA, Sansom DM, Narendran P. Expression and function of the autoimmune regulator (Aire) gene in non-thymic tissue. Clin Exp Immunol. 2011;163:296-308.
140. Wang CY, Shi JD, Davoodi-Semiromi A, She JX. Cloning of Aire, the mouse homologue of the autoimmune regulator (AIRE) gene responsible for autoimmune polyglandular syndrome type 1 (ASP1). Genomics. 1999;55:322-326.
141. Mittaz L, Rossier C,HeinoM, et al. Isolation and characterization of the mouse Aire gene. Biochem Biophys Res Commun. 1999;255:483-490.
142. Kuroda N, Mitani T, Takeda N, et al. Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of Aire-deficientmice. J Immunol. 2005;174:1862-1870.
143. P̈ontynen N, Miettinen A, Arstila TP, et al. Aire deficient mice do not develop the same profile of tissue-specific autoantibodies as APECED patients. J Autoimmun. 2006;27:96-104.
144. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J ExpMed. 1997;186:1677-1687.
145. Smeltz RB, Wolf NA, Swanborg RH. Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: Implications for autoimmunity. J Immunol. 1999;163:1390-1397.
146. Pignata C, Prasad KVS, HallekM, et al. Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol. 1995;165:211-216.
147. Fort MM, Leach MW, Rennick DM. A role for NK cells as regulators of CD4+ T cells in a transfer model of colitis. J Immunol. 1998;161:3256-3261.
148. Aloj G, Giardino G, Valentino L, et al. Severe combined immunodeficiences: New and old scenarios. Int Rev Immunol. 2012;31:43-65.
149. Mathew P, Crist WM, Furman WL. The use in cytokines in children. Curr Opin Pediatr. 1994;6:58-67.
150. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin EndocrinolMetab. 2006;91:2843-2850.
151. Betterle C, Greggio NA, Volpato M. Autoimmune polyglandular syndrome type 1. J Clin Endocr Metab. 1998;83:1049-1055.
152. Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl JMed. 1990;322:1829-1836.
153. T'oth B, Wolff AS, Hal'asz Z, et al. Novel sequence variation of AIRE and detection of interferonomega antibodies in early infancy. Clin Endocrinol (Oxf). 2010;72:641-647.
154. Wolff AS, Erichsen MM,Meager A, et al. Autoimmune polyendocrine syndrome type 1 in Norway: Phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin EndocrinolMetab. 2007;92:595-603.
155. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: Autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002;23:327-364.
156. Kisand K, Bøe Wolff AS, Podkrajsek KT, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med. 2010;207:299-308.
157. Puel A,D̈offinger R,Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronicmucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207:291-297.
158. Husebye ES, Perheentupa J, Rautemaa R, K̈ampe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J InternMed. 2009;265:514-529.
159. Bensing S, Brandt L, Tabaroj F, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf). 2008;69:697-704.
160. Rautemaa R, Hietanen J, Niissalo S, Pirinen S, Perheentupa J. Oral and oesophageal squamous cell carcinoma - A complication or component of autoimmune polyendocrinopathy-candidiasisectodermal dystrophy (APECED, APS-I). Oral Oncol. 2007;43:607-613.
161. Lankisch TO, Jaeckel E, Strassburg CP. The autoimmune polyendocrinopathy-candidiasisectodermal dystrophy or autoimmune polyglandular syndrome type 1. Semin Liver Dis. 2009; 29:307-314.
162. Capalbo D, Mazza C, Giordano R, et al. Molecular background and genotype-phenotype correlation in APECED patients from Campania and in their relatives. J Endocrinol Invest. 2011; 35:169-173.
163. Capalbo D, Elefante A, Spagnuolo MI, et al. Posterior reversible encephalopathy syndrome in a child during an accelerated phase of a severe APECED phenotype due to an uncommonmutation of AIRE. Clin Endocrinol (Oxf). 2008;69:511-513.
164. Gavanescu I, Benoist C, Mathis D. B cells are required for Aire-deficient mice to develop multiorgan autoinflammation: A therapeutic approach for APECED patients. Proc Natl Acad Sci USA. 2008;105:13009-13014.
165. Devoss JJ, ShumAK, Johannes KP, et al. Effector mechanisms of the autoimmune syndrome in the murine model of autoimmune polyglandular syndrome type 1. J Immunol. 2008;181:4072-4079.
166. Zlotogora J, Shapiro MS. Polyglandular autoimmune syndrome type I among Iranian Jews. JMed Genet. 1992;29:824-826.
167. Aaltonen J, Bjorses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: Autoimmune polyglandular disease type I assigned to chromosome 21. Nat Genet. 1994;8:83-87.
168. Rosatelli MC, Meloni A, Devoto M, et al. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. HumGenet. 1998;103:428-434.
169. Cetani F, Barbesino G, Borsari S, et al. A novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, acting in a dominant fashion and strongly cosegregatingwith hypothyroid autoimmune thyroiditis. J Clin EndocrMetab. 2001;86:4747-4752.
170. Podkrajses KT, Bratanic N, Krzisnik C, Battelino T. Autoimmune regulator-1 messenger ribonucleic acid analysis in a novel intronic mutation and two additional novel AIRE gene mutations in a cohort of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. J Clin EndocrMetab. 2005;90:4930-4935.
171. Stolarski B, Pronicka E, Korniszewski L, et al. Molecular background of polyendocrinopathycandidiasis-ectodermal dystrophy syndrome in a Polish population: Novel AIRE mutations and an estimate of disease prevalence. Clin Genet. 2006;70:348-354.
172. Scott HS, Heino M, Peterson P, et al. Common mutations in autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol. 1998;12:1112-1119.
173. Pearce SH,CheethamT, Imrie H, et al.Acommonand recurrent 13-bp deletion in the autoimmune regulator gene in British kindredswith autoimmune polyendocrinopathy type 1. AmJHumGenet. 1998;63:1675-1684.
174. Dominguez M, Crushell E, Ilmarinen T, et al. Autoimmune polyendocrinopathy-candidiasisectodermal dystrophy (APECED) in the Irish population. J Pediatr Endocrinol Metab. 2006;19: 1343-1352.
175. Wang CY, Davoodi-Semiromi A, Huang W, Connor E, Shi JD, She JX. Characterization of mutations in patients with autoimmune polyglandular syndrome type 1 (APS1). Hum Genet. 1998;103:681-685.
176. HeinoM, Scott HS, Chen Q, et al.Mutation analyses of North American APS-1 patients. HumMutat. 1999;13:69-74.
177. Clemente MG,Meloni A, Obermayer-Straub P, Frau F,Manns MP, De Virgilis S. Two cytochromes P450 aremajor hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology. 1998;114:324-328.
178. Meloni A, Willcox N, Meager A, et al. Autoimmune polyendocrine syndrome type 1: An extensive longitudinal study in Sardinian patients. J Clin EndocrMetab. 2012;97:1114-1124.
179. Meloni A, Perniola R, Faa V, Corvaglia E, Cao A, RosatelliMC.Delineation of the molecular defects in the AIRE gene in autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy patients from Southern Italy. J Clin EndocrinolMetab. 2002;87:841-846.
180. Cervato S, Mariniello B, Lazzarotto F, et al. Evaluation of the autoimmune regulator (AIRE) genemutations in a cohort of Italian patientswith autoimmune-polyendocrinopathy-candidiasisectodermal-dystrophy (APECED) and in their relatives. Clin Endocrinol (Oxf). 2009;70:421-428.
181. Giordano C, Modica R, Allotta ML, et al. Autoimmune polyendocrinopathy- candidiasisectodermal-dystrophy (APECED) in Sicily: Confirmation that R203X is the peculiar AIRE genemutation. J Endocrinol Invest. 2011;35:384-388.
182. Valenzise M, Wasniewska M, Mirabelli S, De Luca F, Cervato S, Betterle C. Identification of two novel mutations in the first Sicilian APECED patient with no R203X mutation in AIRE gene and review of Italian APECED genotypes. Gene. 2012;499:343-346.
183. Betterle C,Ghizzoni L,CassioA, et al.Autoimmune-polyendocrinopathy- candidiasis-ectodermaldystrophy (APECED) in Calabria: Clinical, immunological and genetic patterns. J Endocrinol Invest. [Nov 21, 2011.Epub ahead of print].
184. Ishii T, Suzuki Y, Ando N,Matsuo N, Ogata T. Novelmutations of the autoimmune regulator gene in two siblings with autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy. J Clin EndocrMetab. 2000;85:2922-2926.
185. Halonen M, Eskelin P, Myhre AG, et al. AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy phenotype. J Clin EndocrinolMetab. 2002;87:2568-2574.
186. Kekalainen E, Tuovinen H, Joensuu J, et al. A defect of regulatory T cells in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Immunol. 2007;178:1208-1215.
187. Russell JH, Rush B,Weaver C,Wang R.Mature T cells of autoimmune lpr/lprmice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci U S A. 1993;90:4409-4413.
188. Pignata C, Fiore M,De Filippo S, Cavalcanti M,Gaetaniello L, Scotese I. Apoptosis as amechanism of peripheral bloodmononuclear cell death following measles and varicella-zoster virus infections in children. Pediatr Res. 1998;43:77-83.
189. Giardino G, Aloj G, Cirillo E, et al. Intergenerational anticipation of disease onset in people with multiple autoimmune syndrome. Diabetes Res Clin Pract. 2011;94:37-39.